Chronic Inflammatory Demyelinating Polyneuropathy, Diabetes Mellitus, Peripheral Neuropathy
Conditions
Brief summary
The purpose of this study is to determine whether intravenous immunoglobulin (IVIg) is an effective intervention for patients with diabetes, peripheral neuropathy, and demyelination on nerve conduction studies. All patients will receive both IVIg and placebo for 3 months each, with a 3 month washout period in between.
Detailed description
There is a knowledge gap with regards to the appropriate method of detecting and treating chronic inflammatory demyelinating polyneuropathy (CIDP), in patients with co-existent diabetes. In this pilot study the investigators plan to examine the overlap between diabetic polyneuropathy and CIDP by treating patients with diabetes and demyelinating abnormalities using IVIg. The investigators will enroll diabetes patients with a broad spectrum of demyelinating abnormalities. The proposed trial will be an explanatory, blinded, single-centre, superiority, randomized controlled cross-over trial. Each patient will receive 3 months of 10% intravenous immunoglobulin and 3 months of placebo (0.9% sodium chloride in water) with a 3-month washout period. The primary outcome measure is the mean change in ONLS (Overall Neuropathy Limitation Scale), a measure of disability in polyneuropathy; however secondary outcome measures will consider impairments and quality of life.
Interventions
DRUG10% intravenous immunoglobulin (IVIg)
DRUG0.9% sodium chloride
Sponsors
University Health Network, Toronto
University of Toronto
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years. 2. Diabetes, as per American Diabetes Association Criteria. 3. Clinical evidence of polyneuropathy and NCS shows 2 separate motor nerves (median, ulnar, tibial, or peroneal) which meet criteria for demyelination, defined as follows: 1. Conduction velocity \<90% lower limit of normal (LLN), distal latency \>110% upper limit of normal (ULN), or minimal F-wave latency \>110% ULN 2. The changes are not exclusively due to median neuropathy at the wrist, ulnar neuropathy at the elbow, or peroneal neuropathy at the fibular head. 4. Clinical suspicion of possible demyelinating polyneuropathy (CIDP).
Exclusion criteria
1. Pregnant patients, or those of childbearing potential not using contraception. 2. Patients \<18 years of age. 3. Presence of an alternative etiology of peripheral neuropathy, such as: hereditary neuropathies (Charcot Marie-Tooth disease); B-vitamin deficiency- or excess-related neuropathy; uremic neuropathy; neuropathy secondary to monoclonal gammopathy; history of cancer- or chemotherapy-related neuropathy; other toxin exposures; and alcoholic neuropathy. 4. Contraindication to IVIg, including: history of recurrent thrombosis, immunoglobulin A deficiency, or severe hypersensitivity reaction to IVIg in past, renal failure, recurrent deep venous thrombosis, pulmonary embolus, stroke, or myocardial infarction. 5. Presence of serious or unstable medical condition, which may preclude study completion or lead to inability to tolerate IVIg. This may include active heart failure, uncontrolled hypertension, or severe anemia, among other conditions. 6. Presence of concomitant neurological illness, which may confound evaluation. 7. Fails or unable to provide informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Overall Neuropathy Limitations Score (ONLS) after 3 months | Baseline and 3 months | ONLS score will be measured before and after 3 months of IVIg / placebo |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Nerve Conduction Studies (NCS) after 3 months | Baseline and 3 months | Changes in NCS parameters will be compared before and after 3 months of IVIg / placebo |
| Change in Medical Research Council (MRC) Sum Score after 3 months | Baseline and 3 months | MRC sum score will be compared before and after 3 months of IVIg / placebo |
| Change in Rasch-Built Overall Disability Scale (R-ODS) after 3 months | Baseline and 3 months | R-ODS score will be measured before and after 3 months of IVIg / placebo |
| Change in Short Form 36 (SF-36) Quality of Life after 3 months | Baseline and 3 months | SF-36 will be compared before and after 3 months of IVIg / placebo |
| Adverse Events | 30 days | Number of adverse events and serious adverse events within 30 days of IVIg administration |
| Change in Grip Strength after 3 months | Baseline and 3 months | Grip strength (using Martin vigorimeter) will be compared before and after 3 months of IVIg / placebo |
Countries
Canada
Contacts
Primary ContactEduardo Ng, MD
Outcome results
None listed